170492 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans; Assays involving receptors, cell surface antigens or cell surface determinants; Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
P-SELECTIN MUTANTS AND MODULATION OF INTEGRIN-MEDIATED SIGNALING
#2BIOMARKER PANEL, MICROFLUIDIC DEVICE AND DETECTION KIT FOR CAPTURING CIRCULATING TUMOR CELLS
#3METHODS FOR THE DIAGNOSIS AND TREATMENT OF T-CELL MALIGNANCIES
#4Assays for Quantification of Anti-HPA-1a Antibodies
#5METHODS FOR TREATING DRUG RESISTANT CANCERS
#6Method for Determining Prognosis of Cancer
#7SEROLOGIC ASSAY FOR SILENT BRAIN ISCHEMIA
#8Method for Determining Prognosis of Cancer
#9METHODS FOR PROGNOSING AND PREVENTING METASTATIC LIVER DISEASE
#10SINGLE DOMAIN ANTIBODY TARGETING aVB3 INTEGRIN
#11METHODS AND COMPOSITIONS FOR ANALYZING PLATELETS BY MASS CYTOMETRY
#12BI-FUNCTIONAL ARGININE-GLYCINE-ASPARTIC ACID (RGD) PEPTIDES AND METHODS TO PROMOTE ANGIOGENESIS
#13Compositions and methods for predicting post-surgical cardiovascular events
#14METHODS FOR TREATING DRUG RESISTANT CANCERS
#15SEROLOGIC ASSAY FOR SILENT BRAIN ISCHEMIA
#16Method for Determining Prognosis of Cancer
#17PLATELET ANALYSIS SYSTEM
#18Methods and Compositions For the Treatment of Proteinuric Diseases
#19DIAGNOSTIC ASSAYS FOR SUPAR-β3 INTEGRIN DRIVEN KIDNEY DISEASES
#20Identification of CD8T cells that are CD161and/or IL18R(α)and have rapid drug efflux capacity
#21Methods for prognosing and preventing metastatic liver disease
#22COMPOSITIONS FOR DETECTING CIRCULATING INTEGRIN BETA-3 BIOMARKER AND METHODS FOR DETECTING CANCERS AND ASSESSING TUMOR PRESENCE OR PROGRESSION, CANCER DRUG RESISTANCE AND TUMOR STEMNESS
#23Bi-functional arginine-glycine-aspartic acid (RGD) peptides and methods to promote angiogenesis
#24Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing Parkinson's disease
#25Anti-GPIIB/IIIA antibodies and uses thereof
#26Methods and Compositions for the Treatment of Proteinuric Diseases
#27Methods, devices, and systems for sample analysis
#28Assays for screening for or identifying an agent or molecule that can block or inhibit AVB3 integrin from forming a complex with KRAS
#29Methods for Predicting Cardiovascular Mortality Risk
#30Identification of CD8T cells that are CD161and/or IL18Rαand have rapid drug efflux capacity
#31Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
#32Aptamer Specific to Integrin alpha-v-beta-3 and Use Thereof
#33DIAGNOSIS AND TREATMENT OF ASPIRIN-EXACERBATED RESPIRATORY DISEASE (AERD)
#34Use of integrin beta subunits in the diagnosis of venous thromboembolism
#35STABILIZED LOW AFFINITY CONFORMATION OF INTEGRINS FOR DRUG DISCOVERY
#36Platelet analysis system
#37METHOD FOR SCREENING OSTEOPONTIN INHIBITOR AND INHIBITOR OBTAINED FROM THE METHOD
#38Methods for Predicting Cardiovascular Mortality Risk
#39Preventing and treating sepsis
#40APPLICATION OF 99MTC PEPTIDE-BASED COMPOUND AS A BONE MARROW IMAGING AGENT
#41Identifcation of CD8 T cells that are CD161and/or IL18Rαand have rapid drug efflux capacity
#42Kit for measuring in vivo mutation frequency at an endogenous gene locus
#43Methods and compositions for the treatment of proteinuric diseases
#44Stabilized low affinity conformation of integrins for drug discovery
#45ASSESSING LUNG NODULES
#46Method for enhancing or inhibiting insulin-like growth factor-I
#47Suppression of sPLA2-integrin binding for treating an inflammatory condition
#48Binding Agents
#49Early detection of hemangiosarcoma and angiosarcoma
#50Method for measuring in vivo mutation frequency at an endogenous gene locus
#51High-throughput screening method for intergrin antagonist and new peptide screened therefrom
#52Method and compositions for treating diseases targeting CD51
#53Diagnosis of pancreatic cancer by using pancreatic targets
#54Method for enhancing or inhibiting insulin-like growth factor-I